Additionally, non-small cell lung cancer (NSCLC) may have driver mutations, including EGFR, ALK, ROS1, RET and BRAF10,11 . Furthermore, next-generation sequencing (NGS), such as the OncomineTM Dx Target Test® (ODxTT), to measure multiple gene mutations simultaneously have been used as a companion diagnostic test, but the test failure rate of ODxTT was reported to be up to 28%12. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.